Science Fair Project Encyclopedia
| CAS number |
| ATC code |
|Elimination half-life||4-5 hours|
|Legal status||Schedule 4 (Aust)|
|Routes of administration||oral|
Vardenafil was co-marketed by Bayer Pharmaceuticals and GlaxoSmithKline (GSK) under the trade name Levitra. As of 2005, the co-promotion rights of GSK on Levitra have been "transferred back" to Bayer in many markets outside of the United States. In Italy, Bayer markets the product as Levitra and GSK markets the product as Vivanza.
Main page: PDE5 inhibitor
Indications and contraindications are as for other PDE5 inhibitors.
Adverse drug reactions
More common adverse drug reactions (ADRs) are as per other PDE5 inhibitors and are listed on that page.
Common vardenafil-specific ADRs include: nausea. Infrequent ADRs include: abdominal pain, back pain, photosensitivity, abnormal vision, eye pain, facial oedema, hypertension, palpitation, tachycardia, arthralgia, myalgia, rash, itch, priapism. (Rossi, 2004)
It is available in 2.5 mg, 5 mg, 10 mg, and 20 mg doses in round orange tablets. The normal starting dose is 10 mg (roughly equivalent to 50 mg of sildenafil). Vardenafil should be taken 25-60 minutes prior to sexual activity, with a maximum dose frequency of once per day.
- Rossi S (Ed.) (2004). Australian Medicines Handbook 2004. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-4-2
The contents of this article is licensed from www.wikipedia.org under the GNU Free Documentation License. Click here to see the transparent copy and copyright details